rs397507476
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.
|
19206169 |
2009 |
rs397507476
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
|
18042262 |
2008 |
rs397507476
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
|
16474404 |
2006 |
rs104894421
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs121434629
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
rs121913250
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs61753793
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs6413463
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Collectively, the present results suggest that in the treatment of leukemia, taxodione has potential as a compound with high efficacy to overcome BCR-ABL T315I mutation-mediated resistance in leukemia cells.
|
29859988 |
2018 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.
|
29967475 |
2018 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
|
29321163 |
2018 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
|
28810255 |
2017 |
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we show that retroviral overexpression of Jak2 V617F mutant into wild-type p53 murine bone marrow cells induced polycythemia vera (PV) in the recipient mice, whereas Jak2 V617F-transduced p53-null mice developed lethal leukemia after the preceding PV phase.
|
28068330 |
2017 |
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Leukaemia</span> arising in a JAK2 V617F</span>-negative clone is TP53 independent and shows better survival.
|
28542718 |
2017 |
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In particular, gain-of-function mutations in the <i>JAK</i> genes, most frequently, V617F in the pseudokinase domain of JAK2, have been mapped in patients with blood disorders, including myeloproliferative neoplasms and leukemias.
|
29379470 |
2017 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Surprisingly, inhibition of AurA by AKI603 induced leukemia cell senescence in both BCR-ABL wild type and T315I mutation cells.
|
27824120 |
2016 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In BCR/ABL- or BCR/ABL-T315I-driven murine leukemia as well as in xenograft models of primary Ph+ leukemia harboring the T315I, PF-114 significantly prolonged survival to a similar extent as ponatinib.
|
25394714 |
2015 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we combine comprehensive drug sensitivity and resistance profiling of patient cells ex vivo with structural analysis to establish the VEGFR tyrosine kinase inhibitor axitinib as a selective and effective inhibitor for T315I-mutant BCR-ABL1-driven leukaemia.
|
25686603 |
2015 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph(+)) leukemia, including the recalcitrant BCR-ABL1(T315I) mutant.
|
25132497 |
2014 |
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In mice, tamoxifen treatment blocked development of JAK2(V617F)-induced myeloproliferative neoplasm in vivo, induced apoptosis of human JAK2(V617F+) HSPCs in a xenograft model, and sensitized MLL-AF9(+) leukemias to chemotherapy.
|
25479752 |
2014 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MK-0457 has important activity in patients with leukemias expressing the highly resistant T315I BCR-ABL mutation.
|
22772060 |
2013 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
One mutation, T315I, for example, renders the leukemia resistant to all first- and second-line TKIs.
|
23666688 |
2013 |
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Continued research into how miRNAs impact JAK2(V617F) clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment.
|
23432162 |
2013 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.
|
22985168 |
2012 |
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
|
21926354 |
2011 |